Tryvio — Blue Cross Blue Shield of New Mexico

Initial criteria

• BOTH of the following:
• A. ONE of the following:
• 1. The patient has a diagnosis of hypertension AND ONE of the following:
• A. The patient is still not at blood pressure goal while on triple agent therapy with 3 different antihypertensive therapy classes for at least 4 weeks OR
• B. The patient is unable to be on triple antihypertensive therapy with 3 different antihypertensive therapy classes OR
• 2. The patient has another FDA labeled indication for the requested agent and route of administration AND
• B. If the patient has an FDA labeled indication, then ONE of the following:
• 1. The patient’s age is within FDA labeling for the requested indication for the requested agent OR
• 2. There is support for using the requested agent for the patient’s age for the requested indication AND
• If the patient has a diagnosis of hypertension, then the patient will continue therapy with another antihypertensive agent in combination with the requested agent AND
• The patient does NOT have any FDA labeled contraindications to the requested agent

Reauthorization criteria

• The patient has been previously approved for the requested agent through the plan’s Prior Authorization process AND
• The patient has had clinical benefit with the requested agent AND
• ONE of the following:
• A. The patient has a diagnosis of hypertension, then BOTH of the following:
• 1. The patient is currently treated with another antihypertensive agent(s) AND
• 2. The patient will continue therapy with another antihypertensive agent(s) in combination with the requested agent OR
• B. The patient has another FDA labeled indication for the requested agent and route of administration AND
• The patient does NOT have any FDA labeled contraindications to the requested agent
• The requested agent may also be approved when ONE of the following special conditions applies:
• 1. For BCBS NM Fully Insured or NM HIM members, ALL of the following:
• A. The patient has no FDA labeled contraindications AND
• B. The indication is a rare disease AND
• C. ONE of the following:
• 1. The patient has another FDA labeled indication OR
• 2. The patient has another indication supported in compendia OR
• 2. For Ohio members under Fully Insured or HIM Shop plans, ALL of the following:
• A. The member resides in Ohio AND
• B. The plan is Fully Insured or HIM Shop (SG) AND
• C. The patient has no FDA labeled contraindications AND
• D. ONE of the following:
• 1. The patient has another FDA labeled indication OR
• 2. The patient has an indication supported in compendia OR
• 3. The prescriber has submitted TWO peer-reviewed journal articles supporting the proposed use as generally safe and effective

Approval duration

12 months (BCBSIL/MT) or 3 months (others for initial); 12 months (renewal/special cases)